Astria Biosciences is working to bring new diagnostic and therapeutic tools to cerebrovascular care. The Pittsburgh company is developing a blood-based test to detect cerebral aneurysms and assess their risk, alongside molecular therapies for the disease. Its research has received NSF SBIR Phase I support. [1]
The founding team—Kamil W. Nowicki, Ali A. Alattar, Aditya Mittal, Michael M. McDowell and Robert M. Friedlander—brings together expertise in neurosurgery, statistical analysis and clinical research to advance these development programs. [2]